Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization

Zhang, Qiu-Yan; Zhang, Hong-Qing; Zhang, Ya-Nan; Zhang, Zhe-Rui; Li, Xiao-Dan; Hao, Meng-Chan; Zhang, Yang; Li, Jia-Qi; Hu, Yan-Yan; Chen, Xiao-Ling; Wang, Jing; Shi, Yu-Jia; Deng, Cheng-Lin; Chen, Jian-Jun; Ye, Han-Qing; Zhang, Bo

doi:10.1016/j.antiviral.2023.105757

Antiviral Research

2023

DOI: 10.1016/j.antiviral.2023.105757

|View full text |Cite

Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization

Qiu-Yan Zhang,

Hong-Qing Zhang,

Ya-Nan Zhang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity

Nosaka,

Ohtsuka,

Ohtsuka

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

Human parainfluenza virus type 2 (hPIV2), one of the causative agents of infantile common cold, is a non‐segmented negative‐sense RNA virus with a robust gene expression system. It infects recurrently throughout human life without causing severe disease. Because hPIV2 has a viral envelope that can carry ectopic proteins, we developed a non‐propagative RNA/protein‐carrying vector BC‐PIV by deleting the F gene from hPIV2. BC‐PIV can be vigorously proliferated in the stable packaging cell line Vero/BC‐F cells expressing the hPIV2 F gene but not in other cells. BC‐PIV can deliver exogenous gene(s) on a multigenic RNA genome as an inserted gene fragment(s) and simultaneously deliver exogenous protein(s) on its envelope in a membrane‐anchored form. For example, influenza virus M2e protein, Ebola virus GP protein, and severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) spike protein were shown to be highly expressed in packaging cells and incorporated into the virion. The Ebola virus GP protein and SARS‐CoV‐2 spike protein, each delivered via BC‐PIV, efficiently induced neutralising antibodies against each virus, even after prior treatment with recombinant BC‐PIV in mice and hamsters, respectively. In this review, we describe the properties of BC‐PIV as a promising vaccine vector, and also demonstrate its application as an anti‐tumour virus.

show abstract

Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity

Nosaka,

Ohtsuka,

Ohtsuka

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

Revolutionizing Veterinary Health with Viral Vector-Based Vaccines

Jogi,

Smaraki,

Rajak

et al. 2024

Indian J Microbiol

View full text Add to dashboard Cite

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2

Huang,

Wang,

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization

Cited by 4 publications

References 19 publications

Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity

Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity

Revolutionizing Veterinary Health with Viral Vector-Based Vaccines

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2

Contact Info

Product

Resources

About